Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
Gilles CrochetGloria IacoboniAudrey CouturierEmmanuel BachyJosu Iraola-TruchueloThomas GastinneGuillaume CartronTom FradonBastien LesneMi KwonRomain GounotNuria Martínez-CibrianCristina Castilla-LlorentePau AbrisquetaManuel GuerreiroClémentine SarkozyJosé María Aspa-CillerueloVincent CamusStéphanie GuidezAdrien ChauchetErick DeconinckKrimo BouabdallahFrancesc BoschPere BarbaJudith TrotmanHouot RochPublished in: Blood (2024)
In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.
Keyphrases
- cell therapy
- end stage renal disease
- clinical practice
- diffuse large b cell lymphoma
- stem cells
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute myeloid leukemia
- acute lymphoblastic leukemia
- mesenchymal stem cells
- peritoneal dialysis
- immune response
- dendritic cells
- multiple myeloma
- replacement therapy